Pharmacological peroxisome proliferator-activated receptorγ ligands: emerging clinical indications beyond diabetes

Bibliography

• MANGELSDORF DJ, THUMMEL C, BEATO M et al: The receptor superfamily: the second decade. Cell (1995) 83(6)835–839.
   Google Scholar
• ••Overview of the molecular biology of nuclear transcriptionfactors, best for new-comers to the area.
   Google Scholar
• BRAISSANT 0, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distri-bution of PPAR-a, -6, and -y in the adult rat. Endocri-nology (1996) 137(0:354–366.
   PubMedGoogle Scholar
• VAMECQ J, LATRUFFE N: Medical significance of peroxi-some proliferator-activated receptors. Lancet (1999) 354(9173):141–148.
   PubMed Web of Science ®Google Scholar
• •The most recent general review of the medical significance of PPARs.
   Google Scholar
• KLIEWER SA, WILLSON TM: The nuclear receptor PPARy
   Google Scholar
• - bigger than fat. Curr. Opin. Genet. Dev. (1998) 8(5):576–581.
   Google Scholar
• •Review of PPARs focusing on their ligands and their potential clinical significance.
   Google Scholar
• SPIEGELMAN BM: PPAR-y: adipogenic regulator and receptor. Diabetes (1 9 9 8) 47 (4):507–514.
   Google Scholar
• •Review on importance of PPARy in insulin resistance.
   Google Scholar
• KLIEWER SA, LEHMANN JM, WILLSON TM: Orphan receptors: shifting endocrinology into reverse. Science (1999) 284 (5415) :757–760.
   PubMed Web of Science ®Google Scholar
• SCHULMAN IG, SHAO G, HEYMAN RA: Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor-y (PPARy) heterodimers: intermo-lecular synergy requires only the PPARy hormone-dependent activation function. Mol. Cell. Biol. (1998) 18(6)3483–3494.
   Google Scholar
• MUKHERJEE R, DAVIES PJ, CROMBIE DL et al.: Sensitiza-tion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386 (6623) 407–410.
   PubMed Web of Science ®Google Scholar
• ELSTNER E, MULLER C, KOSHIZUKA K et al.: Ligands for peroxisome proliferator-activated receptor-y and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA (1 9 9 8) 95(15)8806–8811.
   Google Scholar
• ••Provides evidence for potential efficacy of a thiazolidinedi-one in the treatment of breast cancer in humans.
   Google Scholar
• WARRELL RP JR, DE THE H, WANG ZY, DEGOS L: Acute promyelocytic leukemia. New Engl. J. Med. (1993) 329(3)177–189.
   Google Scholar
• ELBRECHT A, CHEN Y, CULLINAN CA et al.: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors yl and y2. Biochem. Biophys. Res. Commun. (1996) 224(2):431–437.
   PubMed Web of Science ®Google Scholar
• GUAN Y, ZHANG Y, DAVIS L, BREYER MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol (1997) 273(6 Pt 2):F1013–F1022.
   Google Scholar
• VIDAL-PUIG AJ, CONSIDINE RV, JIMENEZ-LINAN M et al.: Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weightand regulation by insulin and glucocorticoids. J. Clin. Invest. (1997) 99(102416–2422.
   Google Scholar
• FAJAS L, AUBOEUF D, RASPE E, SCHOONJANS K etal.: The, promoter analysis, and expression of the human PPARy gene. J. Biol. Chem. (1997) 272(30)18779–18789.
   Google Scholar
• ••Good paper on variability of PPARy expression in humans.
   Google Scholar
• ELLIS CN, VARANI J, PERSHADSINGH HA et al.: Troglita- improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-y (PPARy) inhibit keratinocyte proliferation. Arch. Dermatol. (In press.).
   Google Scholar
• ••First demonstration of a therapeutic effect of a thiazolidine-dione on psoriasis in non-diabetic subjects.
   Google Scholar
• PERSHADSINGH HA, BENSON SC, MARSHALL B et al.:Ocular diseases and peroxisome proliferator-activated receptor-y (PPARy) in mammalian eye. Proc. Soc. Neurosci. (1999) (In Press).
   Google Scholar
• FAJAS L, FRUCHART JC, AUWERX J: PPARy3 mRNA: a distinct PPARy mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 438:55–60.
   PubMed Web of Science ®Google Scholar
• HENRY RR: Thiazolidinediones. Endocrinol. Metab. North Am. (1997) 26(3):553–573.
   PubMed Web of Science ®Google Scholar
• KURTZ TW, GARDNER DG: Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension (1998) 32 (3) 380–386.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review on control of gene transcription andPPARy activation as a new approach to treating hypertension.
   Google Scholar
• HAIGH D, ALLEN G, BIRRELL HC et al.: Non-thiazolidinedione antihyperglycaemic agents. Part 3: The effects of stereochemistry on the potency of a-methoxy-6-phenylpropanoic acids. Bioorg. Med. Chem. (1999) 7(5):821–830.
   Google Scholar
• HENKE BR, BLANCHARD SG, BRACKEEN MF et al: N-(2-Benzoylpheny1)-L-tyrosine PPARy agonists. 1. Discovery of a novel series of potent antihypergly-cemic and antihyperlipidemic agents. J. Med. Chem. (1998) 41(25): 5020–5036.
   Google Scholar
• BERGER J, LEIBOWITZ MD, DOEBBER TW et al: Novelperoxisome proliferator-activated receptor (PPAR) and PPARy ligands produce distinct biological effects. J. Biol. Chem. (1999) 274(106718–6725.
   Web of Science ®Google Scholar
• XU HE, LAMBERT MH, MONTANA VG et al: Molecularrecognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell. (1999) 3(3):397–403.
   PubMed Web of Science ®Google Scholar
• HENRY RR. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am. J. Med. (1998) 105(1M:205–265.
   Google Scholar
• BROWN KK, HENKE BR, BLANCHARD SG et al. A novel-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes (1999) 48(7):1415–1424.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, WHITCOMB RW: Hepatic dysfunction associated with troglitazone. New Engl. J. Med. (1998) 338(13):916–917.
   PubMed Web of Science ®Google Scholar
• AMOWITZ LL, SOBEL BE: Cardiovascular consequences of polycystic ovary syndrome. Endocrinol. Metab. North Am. (1999) 28(2):439–458.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al.: Troglita-zone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1997) 82 (7) :2108–2116.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D, QUINTANA B, WHITCOMB R: The insulin-sensitizing agent troglita-zone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J.. Metab. (1996) 81 (9):3299–3306.
   PubMed Web of Science ®Google Scholar
• •Clinical study on the effects of a thiazolidinedione on sex hormone abnormalities in a gynaecological endocrine disease.
   Google Scholar
• ANDREWS RC, WALKER BR: Glucocorticoids and insulinresistance: old hormones, new targets. Clin. Sci. (Colch.). (1999) 96 (5) :513–523.
   Google Scholar
• OKUMURA S, TAKEDA N, TAKAMI K et al: Effects oftroglitazone on dexamethasone-induced insulin resistance in rats. Metabolism (1998) 47(3) :351–354.
   PubMed Web of Science ®Google Scholar
• FONSECA VA, VALIQUETT TR, HUANG SM, GHAZZI MN, WHITCOMB RW: Troglitazone monotherapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, controlled study. The Troglita-zone Study Group. J. Clin. Endocrinol. Metab. (1998) 83 (9):3169–3176.
   PubMed Web of Science ®Google Scholar
• ZHANG HY, REDDY SR, KOTCHEN TA: Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension (1994) 24 (1):106–110.
   PubMed Web of Science ®Google Scholar
• ••Excellent paper demonstrating that the antihypertensiveeffect of pioglitazone is not necessarily related to insulin resistance.
   Google Scholar
• OGIHARA T, RAKUGI H, IKEGAMI H, MASUO K: Enhance- of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. (1995) 8(3):316–320.
   PubMed Web of Science ®Google Scholar
• •First demonstration in humans of an antihypertensive effect of a thiazolidinedione.
   Google Scholar
• SUNG BH, IZZO JL, JR, DANDONA P, WILSON MF: Vasodi-latory effects of troglitazone improve blood pressure at rest and during mental stress in Type 2 diabetes mellitus. Hypertension (1999) 34 (7) 83–88.
   PubMedGoogle Scholar
• NAKAMURA Y, OHYA Y, ONAKA U, FUJII K, ABE I, FUJISHIMA M: Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol (1998) 123:675–682.
   PubMed Web of Science ®Google Scholar
• ITOH H, DOI K, TANAKA T et al.: Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor-y. Clin. Exp. Pharmacol. Physic)]. (1999) 26(7):558–560.
   PubMed Web of Science ®Google Scholar
• FUJISHIMA S, OHYA Y, NAKAMURA Y, ONAKA U, ABE I, M: Pioglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am. J. Hypertens. (1998) 11(9):1134–1137.
   PubMed Web of Science ®Google Scholar
• •Evidence for a beneficial effect of a thiazolidinedione on endothelial function in man.
   Google Scholar
• MURAKAMI T, MIZUNO S, OHSATO K et al.: Effects of on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am. J. Cardiol (1999) 84(0:92-94. A8.
   Google Scholar
• •First demonstration of a therapeutic effect of a thiazolidine-dione on angina pectoris in humans.
   Google Scholar
• TACK CJ, SMITS P, DEMACKER PN, STALENHOEF AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care (1998) 21(5):796–799.
   PubMed Web of Science ®Google Scholar
• YAMASAKI Y, KAWAMORI R, WASADA T et al.: Pioglita-zone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku. J. Exp. Med. (1997) 183 (3):173–183.
   Google Scholar
• ROSS R: Atherosclerosis-an inflammatory disease. New Engl. J. Med. (1999) 340(2):115–126.
   PubMed Web of Science ®Google Scholar
• MORIKANG E, BENSON SC, KURTZ TW, PERSHADSINGH HA: Effects of thiazolidinediones on growth and differ-entiation of human aorta and coronary myocytes. Am. Hypertens. (1997) 10(4 Pt 0:440–446.
   Google Scholar
• RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation. Nature (1998) 391 (6662):79–82.
   PubMed Web of Science ®Google Scholar
• •First article to demonstrate inhibitory effect of PPARy agonists on MMP activity.
   Google Scholar
• JIANG C, TING AT, SEED B: PPAR-y agonists inhibit of monocyte inflammatory cytokines. Nature. (1998) 391 (6662):82–86.
   PubMed Web of Science ®Google Scholar
• •Article on anti-inflammatory effects of PPARy agonists in macrophages.
   Google Scholar
• PLUTZKY J: Atherosclerotic plaque rupture: emerging insights and opportunities. Am. J. Cardiol. (1999) 84 (1A) :15J–20J.
   Google Scholar
• MARX N, SUKHOVA G, MURPHY C, LIBBY P, PLUTZKY J: Macrophages in human atheroma contain PPARy: differentiation-dependent peroxisomal proliferator-activated receptor-y(PPARy) expression and reduction of MMP-9 activity through PPARy activation in mononuclear phagocytes in vitro. Am. J. Pathol (1998) 153 (1):17–23.
   PubMed Web of Science ®Google Scholar
• •Comprehensive study on PPARy activation and inhibition of MMP-9 enzyme activity and gene expression.
   Google Scholar
• FONSECA VA, REYNOLDS T, HEMPHILL D et al.: Effect of on flbrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Complications (1998) 12(4):181–186.
   PubMed Web of Science ®Google Scholar
• CHINETTI G, GRIGLIO S, ANTONUCCI M et al.: Activation proliferator-activated receptors and induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. (1998) 2 73 (40):25573–25580.
   Google Scholar
• ••Excellent article providing explanation for controversialpro-atherogenic role of PPARy activation in monocyte/macrophages.
   Google Scholar
• MINAMIKAWA J, TANAKA S, YAMAUCHI M, INOUE D, H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab. (1998) 83(5):1818–1820.
   PubMed Web of Science ®Google Scholar
• ••First demonstration in humans that a thiazolidinedioneameliorates atherosclerosis.
   Google Scholar
• IGARASHI M, TAKEDA Y, ISHIBASHI N: Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm. Metab. Res. (1997) 29(9):444–449.
   PubMed Web of Science ®Google Scholar
• TAKAGI T, YOSHIDA K, AKASAKA T et al: Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with Type 2 diabetes mellitus: a serial intravascular ultrasound study. J. Am. Coll. Cardiol. (1999) 33:100A.
   Google Scholar
• ••First demonstration in humans that a thiazolidinedioneprevents arterial restenosis after an invasive vascular procedure.
   Google Scholar
• YOSHIMOTO T, NARUSE M, NISHIKAWA M et al.: Antihy- and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. (1997) 272(6 Pt 1):E989–E996.
   Google Scholar
• LYDAKIS C, LIP GY: Microalbuminuria and cardiovas-cular risk. QJM (1998) 91(6):381–391.
   PubMedGoogle Scholar
• IMANO E, KANDA T, NAKATANI Y et al.: Effect of troglita-zone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care (1 9 9 8) 2 1 (12):2135–2139.
   Google Scholar
• •First demonstration in humans that a thiazolidinedione reverses diabetic nephropathy.
   Google Scholar
• MILLER JW: Vascular endothelial growth factor and ocular neovascularization. Am. J. Pathol. (1997) 151(0:13–23.
   PubMedGoogle Scholar
• ISHIBASHI T, MURATA T, HANGAI M: Advanced glycation end products in age-related macular.Arch.Ophthalmol.(1 9 9 8)116(12)1629–1632.
   Google Scholar
• MURATA T, NAGAI R, ISHIBASHI T, INOMUTA H, IKEDA K, HORIUCHI S: The relationship between accumula-tion of advanced glycation end products and expres-sion of vascular endothelial growth factor in human diabetic retinas. Diabetologia (1997) 40(7)764–769.
   Google Scholar
• XIN X, YANG S, KOWALSKI J, GERRITSEN ME: Peroxi-some proliferator-activated receptory ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. (1999) 274(13):9116–9121.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the anti-angiogenic potential ofPPARy activation.
   Google Scholar
• MURATA T, HE S, HANGAI M, RYAN SJ, LAW RE, HINTON: Peroxisome proliferator-activated receptor (PPAR)-y ligands inhibit intraocularThe Proceedings of the Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, USA (1999):918.
   Google Scholar
• ••First demonstration that thiazolidinedione PPARy agonistsmay be a treatment for neovascular retinopathy.
   Google Scholar
• CURSIEFEN C, KUCHLE M, NAUMANN GO: Angiogenesis corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea (1998) 17(6):611–613.
   PubMed Web of Science ®Google Scholar
• FINI ME, PARKS WC, RINEHART WB et al.: Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am. J. Pathol. (1996) 149(4):1287–1302.
   PubMed Web of Science ®Google Scholar
• SASAKI H, FUKUSHIMA M: Prostaglandins in the treatment of cancer. AntiCancer Drugs (1994) 5(2):131–138.
   PubMed Web of Science ®Google Scholar
• BISHOP-BAILEY D, HLA T: Endothelial cell apoptosis Induced by the peroxisome proliferator-activated receptory (PPARy) ligand 15-deoxy-12'14_prostaglandin J2. J. Biol. Chem. (1999) 274:17042–17048.
   PubMed Web of Science ®Google Scholar
• FUJIMURA S, SUZUMIYA J, NAKAMURA K, ONO J: Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int. J. Oncol. (1998) 13(6):1263–1267.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI N, OKUMURA T, MOTOMURA W, FUJIMOTO Y, KAWABATA I, KOHGO Y: Activation of PPARy inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. (1999) 455(1-2):135–139.
   PubMed Web of Science ®Google Scholar
• SYLVESTER AM, CHEN D, KRASINSKI K, ANDRES V: Role of c-fos and E2F in the induction of cyclin A transcrip-tion and vascular smooth muscle cell proliferation. J. Clin. Invest. (1998) 101(5)940–948.
   Google Scholar
• ALTIOK S, XU M, SPIEGELMAN BM: PPARy induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. (1997) 11(15):1987–1998.
   PubMed Web of Science ®Google Scholar
• •Article on potential molecular mechanism of PPARy-induced growth arrest.
   Google Scholar
• MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal of human breast cancer through PPARy. Mol. Cell (1998) 1(3):465–470.
   PubMed Web of Science ®Google Scholar
• •Article on the antitumour effect of a thiazolidinedione and the differential expression of PPARy in both hormone-dependent and hormone-independent breast cancer cells.
   Google Scholar
• KUBOTA T, KOSHIZUKA K, WILLIAMSON EA et al.: Ligand peroxisome proliferator-activated receptor-y (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. (1998) 58(15):3344–3352.
   PubMed Web of Science ®Google Scholar
• •Article on the antitumour effect of a thiazolidinedione in hormone-dependent and hormone-independent human prostate cancer cell lines, and the potential efficacy of PPARy ligands in the treatment of prostate cancer.
   Google Scholar
• CAMP HS, TAFURI SR, LEFF T: c-Jun N-terminal kinase peroxisome proliferator-activated receptor-yl and negatively regulates its transcrip-tional activity. Endocrinology (1999) 140(1)392–397.
   Google Scholar
• DEMETRI GD, FLETCHER CD, MUELLER E et al. Induction solid tumor differentiation by the peroxisome-activated receptor-y ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA (1999) 96(7):3951–3956.
   PubMed Web of Science ®Google Scholar
• ••First clinical demonstration of an anticancer effect of athiazolidinedione.
   Google Scholar
• SARRAF P, MUELLER E, JONES D et al.: Differentiation and reversal of malignant changes in colon cancer through PPARy. Nature Med. (1998) 4 (9):1046–1052.
   PubMed Web of Science ®Google Scholar
• SU CG, WEN X, BAILEY ST et al.: A novel therapy for colitis utilizing PPAR-y ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. (1999) 104(4)383-389. P, MUELLER E, SMITH WM et al.: Loss-of-function mutations in PPARy associated with human colon cancer. Mol. Cell. (1999) 3(6):799–804. article on differential effects of PPARy agonists depending on functional mutation in the PPARy receptor. E, TONTONOZ P, NELSON MC et al.: Activators of the nuclear receptor PPARy enhance colon polyp formation. Nature Med. (1998) 4 (9) :1058–106.
   Google Scholar
• LEFEBVRE AM, CHEN I, DESREUMAUX P et al: Activation of the peroxisome proliferator-activated receptor-y promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med. (1998) 4(9):1053–1057.
   PubMed Web of Science ®Google Scholar
• GELMAN L, FRUCHART JC, AUWERX J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflam-mation and cancer. Cell. Mol. Life Sci. (1999) 55 (6-7):932–943.
   PubMed Web of Science ®Google Scholar
• •Most recent article on regulation of PPARy?transcriptional activity by their nuclear co-factors and the role of PPARs in inflammation and cancer.
   Google Scholar
• HIMELSTEIN BP, CANETE-SOLER R, BERNHARD EJ, DILKS DW, MUSCHEL RJ: Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis (1994–95) 14 (1–6):246–258.
   Google Scholar
• ITOH T, TANIOKA M, MATSUDA H et al.: Experimental metastasis is suppressed in MMP-9 deficient mice. Clin. Exp. Metastasis (1999) 17 (2) :177–181.
   PubMed Web of Science ®Google Scholar
• REDDY KB, KRUEGER JS, KONDAPAKA SB, DIGLIO CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int. J. Cancer. (1999) 82(2):268–273.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN E, ARAP W, VALTANEN H: Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol (1999) 17(8):768–774.
   PubMed Web of Science ®Google Scholar
• •Review on targeting metalloproteinase inhibition as an approach to preventing tumour metastasis.
   Google Scholar
• VEIKKOLA T, ALITALO K: VEGFs, receptors and angiogenesis. Semin. Cancer Biol. (1999) 9 (3):211–220.
   PubMed Web of Science ®Google Scholar
• BALSARI A, MAIER JA, COLNAGHI MI, MENARD S: Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab. Invest. (1999) 79(7)897–902.
   Google Scholar
• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. New Engl. J. Med. (1995) 332(9):581–588.
   PubMed Web of Science ®Google Scholar
• RIVIER M, SAFONOVA I, GRIFFITHS CEM, AILHAUD G, MICHER S: Differential expression of peroxisome proliferator activated receptor subtypes during the differentiation of human keratinocytes. J. Invest. Dermatol. (1998) 111:1116–1121.
   PubMed Web of Science ®Google Scholar
• VAN RUISSEN F, VAN DE KERKHOF PC, SCHALKWIJK J: Signal transduction pathways in epidermal prolifera-tion and cutaneous inflammation. Clin. Dermatol. (1995) 13(2):161–190.
   PubMed Web of Science ®Google Scholar
• BARKER JN: Psoriasis as a T cell-mediated autoimmune disease. Hosp. Med. (1998) 59(7):530–533.
   PubMed Web of Science ®Google Scholar
• MIZUTANI H, OHMOTO Y, MIZUTANI T, MURATA M, SHIMIZU M: Role of increased production of monocytes TNF-a, IL-1 and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J. Dermatol Sci. (1997) 14(2):145–153.
   PubMed Web of Science ®Google Scholar
• GIORGINI AE, BEALES PE, MIRE-SLUIS A, SCOTT D, LIDDI R, POZZILLI P: Troglitazone exhibits immunomodula-tory activity on the cytokine production of activated human lymphocytes. Horm. Metab. Res. (1999) 31(1):1–4.
   PubMed Web of Science ®Google Scholar
• TANAKA T, ITOH H, DOI K et al: Down regulation of peroxisome proliferator-activated receptor expres-sion by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia (1999) 42(6)702–710.
   Google Scholar
• ELLIS CN, KANG S, VINIK Al, GREKIN RC, CUNNINGHAM WJ, VOORHEES JJ: Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate. Arch. Dermatol. (1987) 123(4):471–475.
   PubMed Web of Science ®Google Scholar
• TALLMAN MS, ANDERSEN JW, SCHIFFER CA et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl. J. Med. (1997) 337(15):1021–1028.
   PubMed Web of Science ®Google Scholar
• ORFANOS CE, ZOUBOULIS CC, ALMOND-ROESLER B, GEILEN CC: Current use and future potential role of retinoids in dermatology. Drugs (1997) 53 (3):358–388.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, LENHARD JM, OLIVER BB, RINGOLD GM, KLIEWER SA: Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. (1997) 272(6):3406–3410.
   PubMed Web of Science ®Google Scholar
• NEURATH. MF, FUSS I, SCHURMANN G et al.: Cytokine gene transcription by NF-?B family members in patients with inflammatory bowel disease. Ann. NY Acad. Sci. (1998) 859:149–159.
   Google Scholar
• DESREUMAUX P, ERNST 0, GEBOES K et al.: Inflamma-tory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 117(0:73–81.
   Google Scholar
• •Evidence for PPARy activation as a rational approach to the treatment of Crohn's disease.
   Google Scholar
• BAERT FJ, RUTGEERTS PR: Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indica-tions. Int. J. Colorectal Dis. (1999) 14 (0 :47–51.
   PubMedGoogle Scholar
• BRENNAN FM, MAINI RN, FELDMANN M: Cytokine expression in chronic inflammatory disease. Br. Med. Bull. (1995) 51(2):368–384.
   PubMed Web of Science ®Google Scholar
• FEARON U, REECE R, SMITH J, EMERY P, VEALE DJ: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann. NY Acad. Sci. (1999) 878:619–821.
   PubMed Web of Science ®Google Scholar
• AMIN AR, ATTUR M, ABRAMSON SB: Nitric oxide synthase and cyclooxygenases: distribution, regula-tion, and intervention in arthritis. Curr. Opin. Rheumatol. (1999) 11(3):202–209.
   PubMedGoogle Scholar
• OBERFIELD JL, COLLINS JL, HOLMES C: A peroxisome proliferator-activated receptor-y ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA (1999) 96(10:6102–6106.
   PubMedGoogle Scholar
• ••First article to describe the synthesis, and cellular andmolecular properties of a PPARy antagonist.
   Google Scholar
• REME CE, GRIMM C, HAFEZI F, MARTI A, WENZEL A: Apoptotic cell death in retinal degenerations. Prog. Retin. Eye Res. (1998) 17(4):443–464.
   PubMed Web of Science ®Google Scholar
• MICHEL PP, LAMBENG N, RUBERG M: Neuropharma-cologic aspects of apoptosis: significance for neurode-generative diseases. Clin. Neuropharmacol (1999) 22(3):137–150.
   PubMedGoogle Scholar
• BENNETT J, ZENG Y, BAJWA R, KLATT L, LI Y, MAGUIRE AM: Adenovirus-mediated delivery of rhodopsin-promoted bc1-2 results in a delay in photoreceptor cell death in the rd/rd mouse. Gene Ther. (1998) 5 (9):1156–1164.
   PubMed Web of Science ®Google Scholar
• SAILLE C, MARIN P, MARTINOU JC, NICOLE A, LONDON J, CEBALLOS-PICOT I: Transgenic murine cortical neurons expressing human Bc1-2 exhibit increased resistance to amyloid 8-peptide neurotoxicity. Neuroscience (1999) 92 (4):1455–1463.
   PubMed Web of Science ®Google Scholar
• ISNER JM, LOSORDO DW: Therapeutic angiogenesis for heart failure. Nature Med. (1999) 5(5):491–492. A Pershadsingh Medical Center, 1830 Flower Street, Bakersfield, CA 93305,.: +1 661 326 2113; Fax: +1 661 326 2114;: [email protected]
   Google Scholar